Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women

International Journal of Cancer

Volumn 137, Issue 4, 2015, Pages 776-783

  Chung, Tony K H ^a   Van Hummelen, Paul ^b   Chan, Paul K S ^a   Cheung, Tak Hong ^a   Yim, So Fan ^a   Yu, Mei Y ^a   Ducar, Matthew D ^b   Thorner, Aaron R ^b   Macconaill, Laura E ^b   Doran, Graeme ^b   Pedamallu, Chandra Sekhar ^b,c   Ojesina, Akinyemi I ^b,c   Wong, Raymond R Y ^d   Wang, Vivian W ^e   Freeman, Samuel S ^c   Lau, Tat San ^a   Kwong, Joseph ^a   Chan, Loucia K Y ^a   Fromer, Menachem ^f   May, Taymaa ^g   Worley, Michael J ^b   Esselen, Katharine M ^b   Elias, Kevin M ^b   Lawrence, Michael ^c   Getz, Gad ^c   Smith, David I ^e   Crum, Christopher P ^b   Meyerson, Matthew ^b,c   Berkowitz, Ross S ^b   Wong, Yick Fu ^a,b   more..

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e MAYO CLINIC   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

cervical adenocarcinoma; genomic alternations; HPV

Indexed keywords

ADULT; AGED; ARID1A GENE; ARTICLE; CANCER STAGING; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; ERBB2 GENE; EXOME; FAT1 GENE; FEMALE; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC DISORDER; HONG KONG; HUMAN; HUMAN TISSUE; MIDDLE AGED; MUTATIONAL ANALYSIS; PAPILLOMAVIRUS INFECTION; PIK3CA GENE; PRIORITY JOURNAL; SOMATIC MUTATION; TUMOR GENE; UTERINE CERVIX CARCINOMA; VIRUS GENOME; WART VIRUS; ADENOCARCINOMA; GENETICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; NEOPLASM STAGING; PAPILLOMAVIRIDAE; PATHOGENICITY; PATHOLOGY; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADENOCARCINOMA; ADULT; AGED; EXOME; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HONG KONG; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PAPILLOMAVIRIDAE; UTERINE CERVICAL NEOPLASMS;

EID: 84931562257     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29456     Document Type: Article

References (34)

1. GLOBOCAN 2012. Cervical Cancer Incidence, Mortality and Prevalence Worldwide in 2012. International Agency for Research on Cancer, WHO. Available at: http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx. Accessed May 22, 2014.
2. Adegoke O, Kulasingam S, Virnig B,. Cervical cancer trends in the united states: a 35-year population-based analysis. J Womens Health 2012; 21: 1031-7.
3. Steren A, Nguyen HN, Averette HE, et al., Radical hysterectomy for stage IB adenocarcinoma of the cervix: The University of Miami experience. Gynecol Oncol 1993; 48: 355-9.
4. Bulk S, Berkhof J, Bulkmans NW, et al., Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in the Netherlands. Br J Cancer 2006; 94: 171-5.
5. Wang SS, Hildesheim A,. Chapter 5: viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr 2003; 31: 35-40.
6. Demichelis F, Greulich H, Macoska JA, et al., SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines. Nucleic Acids Res 2008; 36: 2446-56.
7. Hettmer S, Teot LA, van Hummelen P, et al., Mutations in hedgehog pathway genes in fetal rhabdomyomas. J Pathol 2013; 231: 44-52.
8. Lawrence MS, Stojanov P, Polak P, et al., Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214-8.
9. Lee J, van Hummelen P, Go C, et al., High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. PLoS One 2012; 7: e38892
10. Mermel CH, Schumacher SE, Hill B, et al., GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 2011; 12: R41
11. Kostic AD, Ojesina AI, Pedamallu CS, et al., PathSeq: software to identify or discover microbes by deep sequencing of human tissue. Nat Biotechnol 2011; 29: 393-6.
12. Cibulskis K, Lawrence MS, Carter SL, et al., Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013; 31: 213-9.
13. Banerji S, Cibulskis K, Rangel-Escareno C, et al., Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012; 486: 405-9.
14. Gao J, Aksoy BA, Dogrusoz U, et al., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1.
15. Burke JE, Perisic O, Masson GR, et al., Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA). Proc Natl Acad Sci USA 2012; 109: 15259-64.
16. Adzhubei IA, Schmidt S, Peshkin L, et al., A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248-9.
17. Herter-Sprie GS, Greulich H, Wong KK., Activating mutations in ERBB2 and their impact on diagnostics and treatment. Front Oncol 2013; 3: 86.
18. Ojesina AI, Lichtenstein L, Freeman SS, et al., Landscape of genomic alterations in cervical carcinomas. Nature 2014; 506: 371-5.
19. Liang H, Cheung LW, Li J, et al., Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 2012; 22: 2120-9.
20. Rudd ML, Price JC, Fogoros S, et al., A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res 2011; 17: 1331-40.
21. German S, Aslam HM, Saleem S, et al., Carcinogenesis of PIK3CA. Hered Cancer Clin Pract 2013; 11: 5
22. Wright AA, Howitt BE, Myers AP, et al., Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer 2013; 119: 3776-83.
23. Janku F, Tsimberidou AM, Garrido-Laguna I, et al., PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011; 10: 558-65.
24. Xia S, Zhao Y, Yu S, et al., Activated PI3K/akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells. Cancer Biother Radiopharm 2010; 25: 317-23.
25. Mohseni M, Park BH,. PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001. J Clin Invest 2010; 120: 2655-8.
26. Morris LGT, Kaufman AM, Gong Y, et al., Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat Genet 2013; 45: 253-61.
27. Doorbar J,. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci 2006; 110: 525-41.
28. Zhao P, Hou L, Farley K, et al., SerpinB1 regulates homeostatic expansion of IL-17+ γδ and CD4+ Th17 cells. J Leukoc Biol 2014; 95: 521-30.
29. Reitz J, Gehrig-Burger K, Strauss JF 3rd, et al., Cholesterol interaction with the related steroidogenic acute regulatory lipid-transfer (START) domains of StAR (STARD1) and MLN64 (STARD3). FEBS J 2008; 275: 1790-802.
30. Jacot W, Fiche M, Zaman K, et al., The HER2 amplicon in breast cancer: topoisomerase IIA and beyond. Biochim Biophys Acta 2013; 1836: 146-57.
31. Narisawa-Saito M, Handa K, Yugawa T, et al., HPV16 E6-mediated stabilization of ErbB2 in neoplastic transformation of human cervical keratinocytes. Oncogene 2007; 26: 2988-96.
32. English DP, Roque DM, Santin AD,. HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. Mol Diagn Ther 2013; 17: 85-99.
33. Ross JS, Ali SM, Wang K, et al., Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies. Gynecol Oncol 2013; 130: 554-9.
34. Wheler J, Hong D, Swisher SG, et al., Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses. Oncotarget 2013; 4: 890-8.